Mealey's (November 16, 2020, 11:01 AM EST) -- PHILADELPHIA — A Pennsylvania federal judge on Nov. 12 said a whistleblower’s claims that Sanofi caused the submission of false claims through its use of advisory boards, speaker programs and educational grants to promote its Taxotere cancer drug can proceed, but she granted dismissal of claims involving sales representative preceptorships and “ad hoc” kickbacks (United States ex rel. Yoash Gohil v. Sanofi United States Services Inc., et al., No. 02-2964, E.D. Pa., 2020 U.S. Dist. LEXIS 211100)....